Deutsch

enlarged text

Lux Biosciences to Present at Upcoming Investor Conferences

--Business Editors/Health/Medical Writers --
--Piper Jaffray 19th Annual Healthcare Conference--
--Lazard Capital Markets Fourth Annual Healthcare Conference--

JERSEY CITY, N.J. (November 20, 2007): -- Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that Ulrich Grau, President and CEO, will present a company overview at the following investment conferences:

19th Annual Piper Jaffray Health Care Conference. The presentation will take place at 12:30 pm ET on Tuesday, November 27th, 2007, at the Pierre Hotel in New York City.

Lazard Capital Markets Fourth Annual Healthcare Conference. The presentation will take place at 2:30 pm ET on Wednesday, November 28th, 2007, at the New York Palace Hotel in New York City. The presentation will be webcast live and may be accessed at http://www.wsw.com/webcast/lz4/lux/. An archived version of the webcast will be available at the same location for 30 days following the presentation.

About Lux Biosciences

Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company's business strategy is characterized by:

• A focus on compounds already marketed or with clinical
  proof-of-concept in non-ophthalmic indications that Lux
  Biosciences will develop as unique, targeted therapies for
  corresponding ophthalmic diseases, with potentially greater
  efficacy and safety than existing treatments.

• A clinical-stage portfolio of projects including: i) LX211, a
  next-generation calcineurin inhibitor that has potential in
  several ophthalmic diseases and, as such, represents a
  pipeline of product opportunities; and ii) LX201, a silicone
  matrix ocular (episcleral) implant that steadily releases
  therapeutic doses of cyclosporine A locally to the eye. Both
  the LUMINATE pivotal clinical program for LX211 for the
  treatment of uveitis, as well as the LUCIDA pivotal clinical
  program with LX201 for the prevention of corneal transplant
  rejection were initiated in early 2007.

• Proprietary product-enabling bio-erodible polymer technologies
  that facilitate targeted and sustained delivery of molecules
  to the eye.

For more information on Lux Biosciences, please visit the company's website at www.luxbio.com.

###

CONTACTS: 

Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201 946 0221
ulrich.grau@luxbio.com 

Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Jkureczka@comcast.net